Desk›Healthcare› Akums Drugs and Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd
BSE 544222 · NSE AKUMS · ISIN INE09XN01023 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹772.50
+1.46%
BSE close, 28 August 2026
₹12,158.69 cr
15.7 cr shares · Small cap
₹2,676.39 cr
as published
109.0× · 5.44×
EPS ₹7.09 · BV ₹142.00
1,348.74 / 111.64
₹ cr, as filed
17
2 selected · 12%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -1.4% |
|---|---|
| Against 52-week low | +88.4% |
| Day change | +1.46% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹7.09 |
|---|---|
| Price / earnings | 108.96× |
| Price / book | 5.44× |
| Book value — derived, price ÷ P/B | ₹142.00 |
| Return on equity | 4.99% |
| Operating margin | 19.02% |
| Net margin | 11.43% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 4.99%
- ROE as published
- 4.99%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 392.28 | 44.84 | 2.93 | 19.02% | 11.43% |
| Mar-26 · Q | 338.37 | 15.20 | 0.99 | 10.88% | 4.49% |
| FY25-26 | 1,348.74 | 111.64 | 7.29 | 15.12% | 8.28% |
Quarter on quarter
- Revenue, quarter on quarter
- +15.9%
- Net profit, quarter on quarter
- +195.0%
- Operating margin, quarter on quarter
- +814 bps
Disclosure profile 17 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Acquisition | 1 |
| Concall Transcript | 1 |
| Selected sub-total | 2 |
| Procedural | |
| Analyst / Investor Meet | 8 |
| General | 4 |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| Trading Window | 1 |
| Procedural sub-total | 15 |
| Total | 17 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
17 filings · 2 selected · busiest 2026-08-10
Filing rhythm · the twelve most recent
2026-08-102026-10-09
SelectedProcedural
Filings
17 in the window · 12 earlier on record
-
9 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
25 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of the Institutional Investors Meets
Company Update / Analyst / Investor Meet View filing →
-
16 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors/Analysts Meet
Company Update / Analyst / Investor Meet View filing →
-
3 September 2026 ·
-
25 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investors/Analysts Meet
Company Update / Analyst / Investor Meet View filing →
-
24 August 2026 ·
Update On Schedule Of The Investors/Analysts Meet To Be Held On August 25, 2026
Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026
Company Update / General View filing →
-
13 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investors/Analysts Meet
Company Update / Analyst / Investor Meet View filing →
-
13 August 2026 ·
Earnings Call Transcript
Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27
Company Update / Earnings Call Transcript View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Outcome
Link of audio recording of Investors/Analysts Conference Call
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
-
10 August 2026 ·
Monitoring Agency Report
Monitoring Agency Report for the quarter ended June 30, 2026
Company Update / General View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY27
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule of the Analysts/ Investor Conference Call (Group Meet) for un-audited financial results of Q1 FY27
Company Update / Analyst / Investor Meet View filing →
-
5 August 2026 ·
Board Meeting Intimation for Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 30Th June, 2026
Akums Drugs And Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve the un-audited ....
Board Meeting / Board Meeting View filing →
-
23 July 2026 ·
Acquisition
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Oriflame India's Manufacturing Business
Company Update / Acquisition View filing →
RSS feed for Akums Drugs and Pharmaceuticals Ltd · the 50 most recent filings